World's Best Scientists 2026 revealed!
Laurent Meijer

Laurent Meijer

Award Badge
Biology and Biochemistry
France
2023

D-Index & Metrics

Biology and Biochemistry

D-Index
103
Citations
46382
World Ranking
1298
National Ranking
25

Research.com Recognitions

  • 2023 - Research.com Biology and Biochemistry in France Leader Award

Overview

Laurent Meijer is affiliated with Perha Pharmaceuticals in France and has contributed extensively to biomedical research, particularly in the fields of Medicine and Biochemistry, Genetics and Molecular Biology. Their work spans 35 publications in Medicine and 29 in Biochemistry, Genetics and Molecular Biology, reflecting a strong focus on molecular and genetic mechanisms relevant to human health.

The scientist's research interests are notably centered on molecular biology, organic chemistry, neurology, public health, genetics, and their intersections. Specific subfields of study include:

  • Molecular Biology
  • Organic Chemistry
  • Neurology
  • Public Health, Environmental and Occupational Health
  • Genetics

Laurent Meijer has contributed to main research topics such as:

  • Down syndrome and intellectual disability research
  • Alzheimer's disease research and treatments
  • Neuroblastoma Research and Treatments
  • Cancer, Hypoxia, and Metabolism
  • Cell death mechanisms and regulation
  • Cystic Fibrosis Research Advances
  • Metabolism, Diabetes, and Cancer

Their recent scientific publications cover key developments in kinase inhibitors, genetic dosage effects, and neurodegenerative pathology treatments. Notable recent papers include:

  • "Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview" (2021) published in International Journal of Molecular Sciences
  • "Comparative Efficacy and Selectivity of Pharmacological Inhibitors of DYRK and CLK Protein Kinases" (2023) published in Journal of Medicinal Chemistry
  • "Increased dosage of DYRK1A leads to congenital heart defects in a mouse model of Down syndrome" (2024) published in Science Translational Medicine
  • "A Small Compound Targeting Prohibitin with Potential Interest for Cognitive Deficit Rescue in Aging mice and Tau Pathology Treatment" (2020) published in Scientific Reports
  • "Leucettinibs, a Class of DYRK/CLK Kinase Inhibitors Inspired by the Marine Sponge Natural Product Leucettamine B" (2023) published in Journal of Medicinal Chemistry

Laurent Meijer's publications have appeared frequently in the following scientific journals:

  • Journal of Medicinal Chemistry
  • Scientific Reports
  • bioRxiv (Cold Spring Harbor Laboratory)
  • International Journal of Molecular Sciences
  • Pharmaceuticals

The scientist collaborates regularly with several researchers, including:

  • Mattias F. Lindberg
  • Emmanuel Deau
  • Yann Hérault
  • Priyanka Gupta
  • Keehn Strange

Laurent Meijer's body of work is characterized by a multidisciplinary approach addressing complex biomedical issues such as intellectual disabilities, neurodegenerative diseases, and cancer metabolism. Their research integrates molecular biology with therapeutic development, contributing to understanding the biochemical basis of human disease and potential treatment strategies.

Best Publications

  • Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor

    Noboru Sato;Laurent Meijer;Laurent Meijer;Leandros Skaltsounis;Paul Greengard

  • Biochemical and Cellular Effects of Roscovitine, a Potent and Selective Inhibitor of the Cyclin‐Dependent Kinases cdc2, cdk2 and cdk5

    Laurent Meijer;Annie Borgne;Odile Mulner;James P.J. Chong

  • Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis

    Laurent Meijer;Deborah J Nelson;Vladimir Riazanski;Aida G Gabdoulkhakova

  • Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors.

    Nathanael S. Gray;Lisa Wodicka;Andy-Mark W. H. Thunnissen;Thea C. Norman

  • Indirubins Inhibit Glycogen Synthase Kinase-3β and CDK5/P25, Two Protein Kinases Involved in Abnormal Tau Phosphorylation in Alzheimer's Disease A PROPERTY COMMON TO MOST CYCLIN-DEPENDENT KINASE INHIBITORS?

    Sophie Leclerc;Matthieu Garnier;Ralph Hoessel;Doris Marko

  • Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases.

    Ralph Hoessel;Sophie Leclerc;Jane A. Endicott;Martin E. M. Nobel

  • GSK-3-Selective Inhibitors Derived from Tyrian Purple Indirubins

    Laurent Meijer;Alexios-Leandros Skaltsounis;Prokopios Magiatis;Panagiotis Polychronopoulos

  • Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine.

    W.F. De Azevedo;S. Leclerc;L. Meijer;L. Havlicek

  • Inhibition of Cyclin‐Dependent Kinases by Purine Analogues

    Walter Filgueira De Azevedo;Sophie Leclerc;Laurent Meijer;Libor Havlicek

  • Pharmacological inhibitors of glycogen synthase kinase 3

    Laurent Meijer;Marc Flajolet;Paul Greengard

  • Pharmacological inhibitors of cyclin-dependent kinases

    Marie Knockaert;Paul Greengard;Laurent Meijer

  • Constitutive Phosphorylation of the Parkinson's Disease Associated α-Synuclein *

    Masayasu Okochi;Jochen Walter;Akihiko Koyama;Shigeo Nakajo

  • cdc2 is a component of the M phase-specific histone H1 kinase: Evidence for identity with MPF

    Dominique Arion;Laurent Meijer;Leonardo Brizuela;David Beach

  • Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons

    James A. Bibb;Gretchen L. Snyder;Akinori Nishi;Zhen Yan

  • Inhibition of cyclin-dependent kinases, GSK-3β and CK1 by hymenialdisine, a marine sponge constituent

    L. Meijer;A. M W H Thunnissen;A. W. White;M. Garnier

  • Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases.

    Panagiotis Polychronopoulos;Prokopios Magiatis;Alexios-Leandros Skaltsounis;Vassilios Myrianthopoulos

  • Paullones are potent inhibitors of glycogen synthase kinase‐3β and cyclin‐dependent kinase 5/p25

    Maryse Leost;Christiane Schultz;Andreas Link;Yong Zhong Wu

  • Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials.

    Laurent Meijer;Eric Raymond

  • Synthesis, anti-inflammatory, analgesic and kinase (CDK-1, CDK-5 and GSK-3) inhibition activity evaluation of benzimidazole/benzoxazole derivatives and some Schiff’s bases

    Sham M Sondhi;Nirupma Singh;Ashok Kumar;Olivier Lozach

  • Roscovitine Targets, Protein Kinases and Pyridoxal Kinase

    Stéphane Bach;Marie Knockaert;Jens Reinhardt;Olivier Lozach

Frequent Co-Authors

Thierry Besson
Thierry Besson University of Rouen
Christian Doerig
Christian Doerig RMIT University
Prokopios Magiatis
Prokopios Magiatis National and Kapodistrian University of Athens
Stefan Knapp
Stefan Knapp Goethe University Frankfurt
Nathanael S. Gray
Nathanael S. Gray Stanford University
Alexios-Leandros Skaltsounis
Alexios-Leandros Skaltsounis National and Kapodistrian University of Athens
Miroslav Strnad
Miroslav Strnad Palacký University, Olomouc
Paul Greengard
Paul Greengard Rockefeller University
Doris Marko
Doris Marko University of Vienna
Jane A. Endicott
Jane A. Endicott Newcastle University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Best Scientists Citing Laurent Meijer

Trending Scientists